CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Phoenix, Arizona, United States and 50 other locations
reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's...
Phase 3
Chandler, Arizona, United States of America and 75 other locations
hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesi...
Phase 2
Phoenix, Arizona, United States
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in p...
Phase 2
Phoenix, Arizona, United States and 49 other locations
or Sham investigational device, Spectris™ AD, for 60 minutes daily for approximately 12 months. Efficacy will be measured using the Integrated Alzheimer's...
Phoenix, Arizona, United States and 68 other locations
This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental declin...
Phase 2
Phoenix, Arizona, United States and 34 other locations
and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...
Phase 1, Phase 2
Phoenix, Arizona, United States and 18 other locations
on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's...
Phase 2
Phoenix, Arizona, United States and 25 other locations
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease....
Phase 3
Gilbert, Arizona, United States and 19 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Phoenix, Arizona, United States and 108 other locations
Clinical trials
Research sites
Resources
Legal